trending Market Intelligence /marketintelligence/en/news-insights/trending/uccgmBdW3vDdL4elS0-ZwA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Loxo Oncology names chief development officer, COO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Loxo Oncology names chief development officer, COO

Loxo Oncology Inc. promoted Nisha Nanda to the post of chief development officer and changed Jacob Van Naarden's title to COO, effective Jan. 2.

Nanda previously worked as senior vice president of development strategy from January 2017 to December 2018 at the Stamford, Conn.-based cancer drug developer.

Van Naarden was chief business officer at Loxo from January 2016 to December 2018 and vice president of corporate development and strategy from May 2014 to December 2015.